Proscia, a pioneering software company transforming pathology with artificial intelligence, has secured $50 million in fresh funding. This latest round, led by global investor Insight Partners, pushes the company’s total funding to $130 million. The capital injection comes after a year of remarkable growth, positioning Proscia as a leader in AI-driven pathology.
Today, Proscia’s Concentriq® platform supports 16 of the world’s top 20 pharmaceutical companies. With its continued expansion, over 22,000 patients are expected to receive diagnoses daily through the platform. This momentum reflects the growing demand for advanced digital tools that enhance precision medicine.
Tackling the Growing Cancer Crisis with AI-Driven Pathology
Cancer cases are rising globally, yet pathology—the foundation of 70% of clinical decisions—remains one of healthcare’s most underserved sectors. Many cancer patients face agonizing delays of two months or more before diagnosis and treatment begin. A shortage of pathologists only worsens this challenge as case volumes increase.
Proscia aims to change that by moving pathology from microscopes to powerful, data-rich digital images. This shift not only streamlines diagnosis but also unlocks insights that can reshape patient care. At the heart of this mission is Concentriq, Proscia’s AI-powered platform designed to accelerate the entire precision medicine journey—from research to diagnosis.
Concentriq: Empowering Precision Medicine at Scale
Concentriq stands out as the only AI-driven pathology platform fueling precision medicine. Its impact spans drug discovery, clinical trials, diagnostics, and biomarker development. By connecting life sciences organizations and labs, the platform helps match more patients with targeted therapies, driving faster, more accurate diagnoses.
David West, CEO of Proscia, shared his excitement about the future:
“We’re in a pivotal era for medicine. Demand for advanced diagnostics is skyrocketing, digital pathology adoption is expanding worldwide, and AI is advancing faster than anyone imagined. With this funding, we’ll ensure more pathologists and researchers can harness this technology and deliver precision medicine to patients faster.”
Backing from Global Investors Who Believe in the Power of AI
Leading the investment, Insight Partners highlighted their long-held belief in the digitization of pathology. “We’ve been waiting for the right player to lead this space,” said Scott Barclay, Managing Director at Insight. “Proscia has proven itself with a growing customer base and a powerful product. It’s positioned perfectly as digital pathology becomes mainstream.”
The funding round also saw participation from AI Capital Partners, Triangle Peak Partners, Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures, and Razor’s Edge.
Fueling Growth, Expanding AI Capabilities, and Strengthening Industry Partnerships
Proscia plans to use the new capital to accelerate commercial growth and deepen its footprint in the life sciences industry. Strategic partnerships with Agilent Technologies and Siemens Healthineers will be key to expanding the platform’s reach.
Beyond growth, Proscia is doubling down on AI innovation. The company will advance Concentriq’s AI core and grow its portfolio of precision medicine applications. Building on Concentriq Embeddings—a feature that speeds AI development by 13 times—Proscia aims to empower researchers and data scientists to develop biomarkers, support clinical trials, and enable companion diagnostics.
A Data-Driven Future for Healthcare
Industry experts are taking note of the rapid changes AI is bringing to pathology. Katie Maloney, Partner at DeciBio, emphasized the broader impact:
“The rise of digital pathology and AI is transforming healthcare into a more connected, data-driven system. This evolution makes precision medicine more achievable, cost-effective, and ultimately more impactful for patients.”
With this latest funding, Proscia is well on its way to redefining how pathology supports the future of precision medicine—making diagnoses faster, discoveries smarter, and treatments more targeted for patients worldwide.
